Abstract:Background: In addition to protein tyrosine kinases, accumulating evidence has shown that protein tyrosine phosphatases (PTPs) are suitable therapeutic targets in cancer. PRL-3 is a PTP member that has been well studied in many malignant tumours. The goal of the present study was to elucidate the role of PRL-3 in hepatocellular carcinoma (HCC), which remains largely unknown. Methods: Bioinformatic and immunohistochemical analyses were performed to analyse PRL-3 expression in HCC tissue samples and determine its clinical relevance. PRL-3 gene copy number variations were evaluated by bioinformatic analysis and quantitative-genomic polymerase chain reaction. The biological functions of PRL-3 were investigated in vivo and vitro. Gene microarray assays, RT-qPCR, western blotting and luciferase experiments were performed to identify the downstream effectors of PRL-3 that mediate its functions in HCC. Results: PRL-3 expression was upregulated in HCC samples from public databases and in cohort samples from our centre. High PRL-3 expression was associated with poor prognosis. Copy number gains and amplification of chromosome 8q24.3 in HCC were determined to be positively correlated with the PRL-3 overexpression. PRL-3 overexpression promoted HCC cell proliferation, migration and adhesion, while its loss had the opposite effects. Further study showed that focal adhesion kinase (FAK) was co-amplified and co-expressed with PRL-3 in HCC. Interestingly, PRL-3 also promoted the phosphorylation of FAK, which subsequently mediated the oncogenic functions of PRL-3 in HCC cells. Moreover, TGFB1 was identified as a downstream molecule of PRL-3. TGF-β signalling was shown to mediate the PRL-3-induced activation of FAK. Furthermore, the p38 and PI3K/AKT pathways were observed to mediate the PRL-3-induced expression of TGFB1 and the subsequent activation of FAK, while the activation of FAK in turn stimulated activation of the p38 and PI3K/AKT pathways, forming a PRL-3-triggered AKT/p38/TGFB1/FAK positive feedback loop. Conclusion: Collectively, our findings indicate that the PTP PRL-3 plays a crucial role in the progression of HCC and provides an example of how co-amplified genes work together in HCC.

PRL-3 Promotes the Malignant Progression of Melanoma Via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1

Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.

Phosphatase of Regenerating Liver-3 Localizes to Cyto-Membrane and is Required for B16F1 Melanoma Cell Metastasis in Vitro and in Vivo

PRL-3 Sirna Inhibits the Metastasis of B16-BL6 Mouse Melanoma Cells in Vitro and in Vivo.

Phosphatase Regenerating Liver 3 Participates in Integrinβ1/FAK-Src/MAPK Signaling Pathway and Contributes to the Regulation of Malignant Behaviors in Hepatocellular Carcinoma Cells

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

PRL-3 Activates NF-κB Signaling Pathway by Interacting with RAP1.

PRL-3 Activates Mtorc1 in Cancer Progression

Metastasis-associated PRL-3 Induces EGFR Activation and Addiction in Cancer Cells

The phosphatase of regenerating liver-3 protein (PRL-3) promotes glioma cell invasiveness by interacting with β3 –tubulin

PRL-3 Promotes Gastric Cancer Migration and Invasion Through a NF-κB-HIF-1α-miR-210 Axis.

PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1.

PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways

PRL-3 Facilitates Hepatocellular Carcinoma Progression by Co-Amplifying with and Activating FAK

PRL1 and PRL3 promote macropinocytosis via its lipid phosphatase activity

Phosphatase of Regenerating Liver-3 (PRL-3) is Associated with Metastasis and Poor Prognosis in Gastric Carcinoma

Prl-3 Promotes Telomere Deprotection and Chromosomal Instability

PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo .

PRL-3 promotes cell adhesion by interacting with JAM2 in colon cancer.

Prl-3 Promotes Epithelial Mesenchymal Transition By Regulating Cadherin Directly

PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin β1-ERK1/2 and-MMP2 signaling